Trevi Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell TRVI and other ETFs, options, and stocks.About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease.
CEOJennifer L. Good
CEOJennifer L. Good
Employees26
Employees26
HeadquartersNew Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded2011
Founded2011
Employees26
Employees26
TRVI Key Statistics
Market cap1.65B
Market cap1.65B
Price-Earnings ratio-35.47
Price-Earnings ratio-35.47
Dividend yield—
Dividend yield—
Average volume2.66M
Average volume2.66M
High today$13.45
High today$13.45
Low today$12.74
Low today$12.74
Open price$13.12
Open price$13.12
Volume1.19M
Volume1.19M
52 Week high$14.39
52 Week high$14.39
52 Week low$3.43
52 Week low$3.43
Stock Snapshot
As of today, Trevi Therapeutics(TRVI) shares are valued at $12.88. The company's market cap stands at 1.65B, with a P/E ratio of -35.47.
During the trading session on 2025-12-12, Trevi Therapeutics(TRVI) shares reached a daily high of $13.45 and a low of $12.74. At a current price of $12.88, the stock is +1.1% higher than the low and still -4.2% under the high.
Trading volume for Trevi Therapeutics(TRVI) stock has reached 1.19M, versus its average volume of 2.66M.
The stock's 52-week range extends from a low of $3.43 to a high of $14.39.
The stock's 52-week range extends from a low of $3.43 to a high of $14.39.
Analyst ratings
100%
of 12 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own TRVI. This list is generated using Robinhood data, and it’s not a recommendation.